
The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence (AI). Traditionally, drug development has been a lengthy, costly, and uncertain process. However, AI offers innovative solutions to accelerate drug discovery, resulting in faster identification of potential drug candidates, more efficient clinical trials, and quicker access to new medicines for patients. This convergence of AI and biotechnology, referred to as "TechBio," represents a paradigm shift in the industry and is creating substantial investment opportunities.